Brief: Northstrive Biosciences, Subsidiary of PMGC Holdings, Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

PMGC Holdings

04/02/2025 14:27

Feb 4 (Reuters) - PMGC Holdings Inc  ELAB.O :
    * PMGC UNIT, NORTHSTRIVE, SAYS PREPARING FOR FDA
INVESTIGATIONAL
NEW DRUG FILING FOR EL-22
    * NORTHSTRIVE - ANTICIPATES TYPE B PRE-IND MEETING WITH FDA
IN Q2
2025

Source text:  ID:nGNX8gZXxS 
Further company coverage:  ELAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))